Prothena Announces Board of Directors Update
Prothena (NASDAQ:PRTA) announced that Oleg Nodelman will step down from the company's Board of Directors to focus on existing and new endeavors. Nodelman, who served on the board for five years since 2019, made significant contributions to the company's current strategy. Board Chair Daniel G. Welch acknowledged Nodelman's strategic impact and his role as a veteran biotechnology investor and advisor. Nodelman expressed confidence in the company's future, particularly noting the anticipated multiple clinical readouts across the portfolio in 2025.
Prothena (NASDAQ:PRTA) ha annunciato che Oleg Nodelman si dimetterà dal Consiglio di Amministrazione dell'azienda per concentrarsi su progetti esistenti e nuovi. Nodelman, che ha fatto parte del consiglio per cinque anni dal 2019, ha dato un contributo significativo alla strategia attuale dell'azienda. Il Presidente del Consiglio Daniel G. Welch ha riconosciuto l'impatto strategico di Nodelman e il suo ruolo di investitore e consulente esperto nel settore delle biotecnologie. Nodelman ha espresso fiducia nel futuro dell'azienda, sottolineando in particolare i molteplici risultati clinici previsti nel portfolio per il 2025.
Prothena (NASDAQ:PRTA) anunció que Oleg Nodelman dejará el Consejo de Administración de la empresa para centrarse en proyectos existentes y nuevos. Nodelman, que ha formado parte de la junta durante cinco años desde 2019, ha realizado contribuciones significativas a la estrategia actual de la empresa. El Presidente de la Junta, Daniel G. Welch, reconoció el impacto estratégico de Nodelman y su papel como inversor y asesor veterano en biotecnología. Nodelman expresó confianza en el futuro de la empresa, destacando en particular los múltiples resultados clínicos anticipados en el portafolio para 2025.
Prothena (NASDAQ:PRTA)가 Oleg Nodelman이 기존 및 새로운 사업에 집중하기 위해 회사 이사회에서 물러나기로 발표했습니다. Nodelman은 2019년부터 5년 동안 이사회에서 활동했으며, 회사의 현재 전략에 중요한 기여를 해왔습니다. 이사회 의장인 Daniel G. Welch는 Nodelman의 전략적 영향력과 그의 노련한 생명공학 투자자 및 고문으로서의 역할을 인정했습니다. Nodelman은 회사의 미래에 대한 확신을 나타내며, 특히 2025년에 포트폴리오 전반에 걸쳐 예상되는 여러 임상 결과를 언급했습니다.
Prothena (NASDAQ:PRTA) a annoncé que Oleg Nodelman quittera le conseil d'administration de l'entreprise pour se concentrer sur des projets existants et nouveaux. Nodelman, qui a été membre du conseil pendant cinq ans depuis 2019, a apporté des contributions significatives à la stratégie actuelle de l'entreprise. Le président du conseil, Daniel G. Welch, a reconnu l'impact stratégique de Nodelman et son rôle en tant qu'investisseur et conseiller chevronné en biotechnologie. Nodelman a exprimé sa confiance dans l'avenir de l'entreprise, en notant particulièrement les multiples résultats cliniques attendus dans le portefeuille pour 2025.
Prothena (NASDAQ:PRTA) gab bekannt, dass Oleg Nodelman aus dem Vorstand des Unternehmens austreten wird, um sich auf bestehende und neue Projekte zu konzentrieren. Nodelman, der seit 2019 fünf Jahre lang im Vorstand saß, hat bedeutende Beiträge zur aktuellen Strategie des Unternehmens geleistet. Der Vorstandsvorsitzende Daniel G. Welch erkannte Nodelmans strategischen Einfluss sowie seine Rolle als erfahrener Biotech-Investor und -Berater an. Nodelman äußerte Vertrauen in die Zukunft des Unternehmens und wies insbesondere auf die erwarteten mehreren klinischen Ergebnisse im Portfolio im Jahr 2025 hin.
- Multiple clinical readouts expected across portfolio in 2025
- Loss of experienced board member with deep biotechnology expertise
“I would like to thank Oleg for his contributions during the past five years. As a veteran biotechnology investor and advisor with deep roots in the biotechnology and scientific communities, Oleg shares Prothena’s mission to deliver life-saving therapies for unmet medical needs caused by diseases of protein dysregulation,” said Daniel G. Welch, Chair of Prothena’s Board of Directors. “The entire board of directors recognizes and appreciates Oleg’s strategic impact since joining the board in 2019.”
“As a long-standing investor in Prothena, I leave the board knowing the company is in good hands. I look forward to the multiple clinical readouts across the portfolio in 2025,” said Nodelman. “I have enjoyed working alongside the other directors and leadership team who have contributed to an industry leading R&D pipeline and a mission to develop transformative medicines for patients and their families.”
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis with cardiomyopathy, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on X (formerly Twitter) @ProthenaCorp.
Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to, among other things, expected milestones in 2025; and the expected timing of reporting data from clinical trials. These statements are based on estimates, projections and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated due to known and unknown risks, uncertainties and other factors, including but not limited to those described in the “Risk Factors” sections of our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 12, 2024, and discussions of potential risks, uncertainties, and other important factors in our subsequent filings with the SEC. We undertake no obligation to update publicly any forward-looking statements contained in this press release as a result of new information, future events, or changes in our expectations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241230726184/en/
Media
Michael Bachner, Senior Director, Corporate Communications
609-664-7308, michael.bachner@prothena.com
Investors
Mark Johnson, CFA, Vice President, Investor Relations
650-417-1974, mark.johnson@prothena.com
Source: Prothena Corporation plc
FAQ
Why is Oleg Nodelman stepping down from Prothena's (PRTA) Board of Directors?
How long did Oleg Nodelman serve on Prothena's (PRTA) Board?
What major events are expected for Prothena (PRTA) in 2025?
What was Oleg Nodelman's contribution to Prothena (PRTA) during his tenure?
